These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38926279)

  • 1. Expression of Multispecific Antibodies.
    Peltret M; Schmid A; Duarte L; Mette R; Giovannini R; Bertschinger M
    Methods Mol Biol; 2024; 2810():161-180. PubMed ID: 38926279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approach.
    Peltret M; Vetsch P; Farvaque E; Mette R; Tsachaki M; Duarte L; Duret A; Vaxelaire E; Frank J; Moritz B; Aillerie C; Giovannini R; Bertschinger M
    J Biotechnol; 2024 Jun; 389():30-42. PubMed ID: 38685416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody process development: Assembly and purification of knob and hole bispecific antibodies.
    Giese G; Williams A; Rodriguez M; Persson J
    Biotechnol Prog; 2018 Mar; 34(2):397-404. PubMed ID: 29193902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies.
    Dimasi N; Fleming R; Wu H; Gao C
    Methods; 2019 Feb; 154():77-86. PubMed ID: 30102989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient and stable CHO expression, purification and characterization of novel hetero-dimeric bispecific IgG antibodies.
    Rajendra Y; Peery RB; Hougland MD; Barnard GC; Wu X; Fitchett JR; Bacica M; Demarest SJ
    Biotechnol Prog; 2017 Mar; 33(2):469-477. PubMed ID: 27977915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency.
    Chen C; Wakabayashi T; Muraoka M; Shu F; Wei Shan C; Chor Kun C; Tim Jang C; Soehano I; Shimizu Y; Igawa T; Nezu JI
    MAbs; 2019; 11(4):632-638. PubMed ID: 30898021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.
    Patke S; Li J; Wang P; Slaga D; Johnston J; Bhakta S; Panowski S; Sun LL; Junttila T; Scheer JM; Ellerman DA
    MAbs; 2017 Apr; 9(3):430-437. PubMed ID: 28125314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.
    Tustian AD; Endicott C; Adams B; Mattila J; Bak H
    MAbs; 2016; 8(4):828-38. PubMed ID: 26963837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
    Bezabeh B; Fleming R; Fazenbaker C; Zhong H; Coffman K; Yu XQ; Leow CC; Gibson N; Wilson S; Stover CK; Wu H; Gao C; Dimasi N
    MAbs; 2017; 9(2):240-256. PubMed ID: 27981887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants.
    Paul S; Connor J; Nesspor T; Haytko P; Boakye K; Chiu ML; Jiang H
    Protein Expr Purif; 2016 May; 121():133-40. PubMed ID: 26826313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of CrossMAb technology for the generation of bi- and multispecific antibodies.
    Klein C; Schaefer W; Regula JT
    MAbs; 2016; 8(6):1010-20. PubMed ID: 27285945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
    Moore GL; Bernett MJ; Rashid R; Pong EW; Nguyen DT; Jacinto J; Eivazi A; Nisthal A; Diaz JE; Chu SY; Muchhal US; Desjarlais JR
    Methods; 2019 Feb; 154():38-50. PubMed ID: 30366098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid optimization and prototyping for therapeutic antibody-like molecules.
    Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
    MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for generating multivalent and bispecific antibody fragments.
    Tomlinson I; Holliger P
    Methods Enzymol; 2000; 326():461-79. PubMed ID: 11036658
    [No Abstract]   [Full Text] [Related]  

  • 18. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.
    Dhimolea E; Reichert JM
    MAbs; 2012; 4(1):4-13. PubMed ID: 22327426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin-binding protein-based affinity chromatography in bispecific antibody purification: Functions beyond product capture.
    Li Y
    Protein Expr Purif; 2021 Dec; 188():105976. PubMed ID: 34537355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.
    Husain B; Ellerman D
    BioDrugs; 2018 Oct; 32(5):441-464. PubMed ID: 30132211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.